MacroChem Corp. (fka MACM)

[OptionMonster]

MacroChem CEO to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference November 6, 2007 in New York City
WELLESLEY HILLS, Mass., Oct. 30 /PRNewswire-FirstCall/ -- Robert J. DeLuccia, President and CEO of MacroChem (OTC Bulletin Board: MACM) (http://www.macrochem.com), will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference being held in NYC from Nov 5-7. Mr. DeLuccia will present on November 6, 2007 at 10:15AM ET in the Hubbard Room at the New York Palace Hotel. He will provide a company overview including its two priority product candidates: EcoNail(R), which is currently in a fully enrolled Phase 2 efficacy trial, and pexiganan, the Company's recently acquired novel topical anti-infective drug for treatment of diabetic foot infection (DFI).

The Conference will include presentations by over 350 companies, as well as experts from the medical, scientific, and investment communities. The conference is attended by investors, venture capitalists, company executives, scientists, and other industry leaders.

A live audio webcast of this presentation can be accessed via http://www.wsw.com/webcast/rrshq12/macm.ob.

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Our lead product candidate is EcoNail, a topically applied SEPA(R)-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. We recently acquired exclusive worldwide license rights to pexiganan, a novel topical anti-infective for the treatment of diabetic foot infection, which has already completed two Phase 3 trials. Our other clinical stage product candidate, Opterone(R), is a topically applied SEPA-based testosterone cream designed to treat male hypogonadism. Our pipeline of clinical-stage and early-stage product candidates is based on our SEPA, MacroDerm(TM) and DermaPass(TM) drug delivery technologies. For more information visit our website, http://www.macrochem.com.

Forward-Looking Statements

With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled 'Risk Factors' in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com.

Contact:
MacroChem: Bernard Patriacca - VP/CFO
[e-mail], [phone]
Investor Relations: The Investor Relations Group, Inc.
Christine Berni/ Joseph Triunfo, [phone]
[e-mail], [e-mail]
Media:
Bill Douglass/ Michaela Heller, [phone]
[e-mail], [e-mail]

SOURCE MacroChem



Source: PR Newswire (October 30, 2007 - 10:03 AM EDT)

News by QuoteMedia
www.quotemedia.com